Program

The 13th International HBV Cure Workshop 2026 will be held in Denver, Colorado on November 4, 2026, right before The Liver Meeting® (TLM) 2026 by AASLD. This highly anticipated workshop brings together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Since its inception in 2014, the International HBV Cure Workshop has been a pivotal scientific platform aimed at accelerating the progress towards finding a cure for HBV.

The HBV treatment landscape is experiencing significant transformations and is on the brink of a paradigm shift. The emergence of numerous new treatment options brings great hope for reducing the disease burden, simplifying treatment protocols, and potentially curing and eradicating HBV infection. To optimize curative treatments for HBV, distinguished speakers from around the world will present the latest therapeutic options.

Wednesday, November 4, 2026
7:30 AM - 8:00 AM																AM Coffee & Pastries
8:00 AM - 8:10 AM																Opening remarks
8:10 AM - 9:40 AM																SESSION I - Biomarkers 08:10 – 08:30 Baseline HBsAg levels in HBsAg loss, functional cure and setpoint after therapy discontinuation 08:30 – 08:50 Partial cure and long-term outcomes: what data do we need? 08:50 – 09:10 Cell-free DNA in disease progression and therapeutic response: Opportunities for host-specific biomarkers. 09:10 – 09:40 Discussion
9:40 AM - 10:00 AM																AM BREAK
10:00 AM - 11:30 AM																SESSION II - Managing Patient Populations 10:00 – 10:20 HBV cure in special populations 10:20 – 10:50 Clinical perspective of novel HBV combination therapies: Efficacy vs. AEs & Complexity? 10:50 – 11:10 How much are patients willing to accept to achieve durable functional cure? 11:10 – 11:30 Discussion
11:30 AM - 12:30 PM																Lunch Break
12:30 PM - 2:30 PM																SESSION III - Industry Session
2:30 PM - 3:00 PM																PM BREAK
3:00 PM - 4:20 PM																SESSION IV - Round table topics 15:00 – 15:20 Antisense oligonucleotides as the backbone for new combination therapies 15:20 – 15:40 How much would effective immunotherapy impact functional cure rates? 15:40 – 16:20 Discussion
4:20 PM - 4:30 PM																Closing Remarks
5:00 PM - 6:30 PM																The Forum for Collaborative Research-HBV Forum 17
6:30 PM - 8:30 PM																NETWORKING RECEPTION